邓贤明DENG Xianming, Ph.D.
教授，博士生导师
Chemical Biology and Medicinal Chemistry Group
课题组组长
电 话:+86-
传 真:+86-
E-mail:xmdeng@xmu.edu.cn
Group web: http://121.192.179.196/lmpe/

2001年，厦门大学化学系化学专业，获理学学士学位；
2006年，中科院上海有机化学研究所有机化学专业，获理学博士学位；
2006年至2011年，哈佛医学院Dana-Farber癌症研究所,博士后研究；
2011年10月起，为厦门大学生命科学学院“闽江****”****，微生物药物课题组学科带头人；
2020年，获国家****科学基金资助。

2001，B.Sc., Xiamen University;
2006, Ph.D., Shanghai Institute of Organic Chemistry (SIOC), Chinese Academy of Sciences.
2006-2011, Research Fellow, Dana-Farber Cancer Institute, Harvard Medical School.
2011.10-, Principal Investigator of Chemical Biology and Medicinal Chemistry Group, School of Life
Sciences, Xiamen University.
2020，Grant Awardee of National Science Foundation For Distinguished Young Scholars.

主要研究领域（Research Area）
化学生物学和药物化学。在化学生物学方面，我们集中于设计并合成新颖的针对蛋白激酶（Protein Kinase）和表观遗传蛋白（Epigenetic Enzyme）的小分子抑制剂，并运用这些功能小分子为工具，发现和解决信号传导通路、神经生物学和癌症中的新问题。在药物化学方面，以化学生物学研究成果为基础，结合传统的药物化学手段（构效关系研究、药代动力学和毒理学研究）进一步优化小分子工具化合物，以期发展针对癌症等相关疾病的“靶向治疗”药物。
Our research is focused on two major areas: chemical biology and medicinal chemistry. At the interface of chemistry and biology, we use organic synthesis to create new chemical tools for studying biological problems in human health and disease. These functional small-molecule tools are applied to control and elucidate cellular signal transduction in cancer, stem cell, and neural diseases. Second, we pursue established medicinal chemistry approaches including structure activity relationship (SAR) study and pharmacokinetics modification to optimize pre-clinical drug candidates. We're working to address the following general questions: a) How can we develop small-molecule modulators with selectivity towards desired targets such as protein kinases and epigenetic enzymes? b) How can we use discovered-small-molecule tools to dissect the molecular signaling pathways? c) How can we develop the 'lead' of targeted-drug from the tool compound?



代表性论文（Selected publications）(^#Co-first authorship,*Corresponding author)：
1. Zhang, J.*; Bhuiyan, M. I. H.; Zhang, T.; Karimy, J. K.; Wu, Z.; Fiesler, V. M.; Zhang, J.; Huang, H.; Hasan, M. N.; Skrzypiec, A. E.; Mucha, M.; Duran, D.; Huang, W.; Pawlak, R.; Foley, L. M.; Hitchens, T. K.; Minnigh, M. B.; Poloyac, S. M.; Alper, S. L.; Molyneaux, B. J.; Trevelyan, A. J.; Kahle, K. T.*; Sun, D.*; Deng, X.*, Modulation of brain cation-Cl? cotransport via the SPAK kinase inhibitor ZT-1a. Nat. Commun., 2020, 11, 78. (Highlighted by The Medical News).
2. Yin, C.; Zhu, B.; Zhang, T.; Liu, T.; Chen, S.; Liu, Y.; Li, X.; Miao, X.; Li, S.; Mi, X.; Zhang, J.; Li, L.; Wei, G.; Xu, Z.; Gao, X.; Huang, C.; Wei, Z.; Goding, C. R.; Wang, P.*;Deng, X.*; Cui, R.* Pharmacological targeting of STK19 inhibits oncogenic NRAS driven melanomagenesis.Cell, 2019, 176, 1113-1127.e16. (Highlighted by Cancer Discovery).
3. Fan, F.; He, Z.; Kong, L. L.; Chen, Q.; Yuan, Q.; Zhang, S.; Ye, J.; Liu, H.; Sun, X.; Geng, J.; Yuan, L.; Hong, L.; Xiao, C.; Zhang, W.; Li, Y.; Wang, P.; Huang, L.; Wu, X.; Ji, Z.; Wu, Q.; Xia, N. S.; Gray, N. S.; Chen, L.; Yun, C. H.*;Deng, X.*; Zhou, D.* Pharmacological targeting of kinases MST1 and MST2 augments tissue repair and regeneration.Sci. Transl. Med.2016, 8, 352ra108. (Cover story, Highlighted by Nature Reviews Gastroenterology & Hepatology)
4. Jiang, J.; Gui, F.; He, Z.; Li, L.; Li, Y.; Li, S.; Wu, X.; Deng, Z.; Sun, X.; Huang, X.; Huang, W.; Han, S.; Zhang, T.; Wang, Z.; Jiao, B.; Song, S.; Wang, H.-R.; Chen, L.; Zhou, D.; Liu, Q.; Ren, R.*; Zhang, J.*; Deng, X.* Targeting BRK-positive breast cancers with small molecule kinase inhibitorsCancer Res. 2017, 77, 175-186. (Highlighted byBioWorld^TM).
5. Huang, W.; Sun, X.; Li, Y.; He, Z.; Li, L.; Deng, Z.; Huang, X.; Han, S.; Zhang, T.; Zhong, J.; Wang, Z.; Xu, Q.; Zhang, J.;Deng, X.* Discovery and Identification of Small Molecules as Methuosis Inducers with in Vivo Antitumor Activities.J. Med. Chem. 2018, 61, 5424-5434. (Top journal in Medicinal Chemistry)
6. Jiang, H.; He, H.; Chen, Y.; Huang, W.; Cheng, J.; Ye, J.; Wang, A.; Tao, J.; Wang, C.; Liu, Q.; Jin, T.; Jiang, W.*;Deng, X.*; Zhou, R.* Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders.J. Exp. Med. 2017, 214, 3219-3238. (Highlighted by Nature Reviews Rheumatology).
7. Gui, F.; Jiang, J.; He, Z.; Li, L.; Li, Y.; Deng, Z.; Lu, Y.; Wu, X.; Chen, G.; Su, J.; Song, S.; Zhang, Y. M.; Yun, C. H.; Huang, X.; Weisberg, E.; Zhang, J.*; Deng, X.*, A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk(C481S) mutation in B-cell malignancies. Br. J. Pharmacol. 2019, 176, 4491-4509.
8. Liu, Z.; Li, Y.; Li, W.; Lian, W.; Kemell, M.; Hietala, S.; Figueiredo, P.; Li, L.; M?kil?, E.; Ma, M.; Salonen, J.; Hirvonen, J. T.; Liu, D.; Zhang, H.*; Deng, X.*; Santos, H. A.*, Close-loop dynamic nanohybrids on collagen-ark with in situ gelling transformation capability for biomimetic stage-specific diabetic wound healing. Materials Horizons 2019, 6, 385-393.
9. Liu, Z.; Li, Y.; Li, W.; Xiao, C.; Liu, D.; Dong, C.; Zhang, M.; M?kil?, E.; Kemell, M.; Salonen, J.; Hirvonen, J. T.; Zhang, H.*; Zhou, D.*; Deng, X.*; Santos, H. A.* Multifunctional Nanohybrid Based on Porous Silicon Nanoparticles, Gold Nanoparticles, and Acetalated Dextran for Liver Regeneration and Acute Liver Failure Theranostics. Adv. Materials 2018, 30, e**.

10. He, H.; Jiang, H.; Chen, Y.; Ye, J.; Wang, A.; Wang, C.; Liu, Q.; Liang, G.; Deng, X.*; Jiang, W.*; Zhou, R.* Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat. Commun.2018, 9, 2550.
11. Huang, X.; Huang, W.; Li, L.; Sun, X.; Song, S.; Xu, Q.; Zhang, L.; Wei, B. G.; Deng, X.* Structure Determinants of Lagunamide A for Anticancer Activity and Its Molecular Mechanism of Mitochondrial Apoptosis. Mol. Pharm.2016, 13, 3756-3763.
12. Wang, Y.; Qi, S.; Zhan, Y.; Zhang, N.; Wu, A.; Gui, F.; Guo, K.; Yang, Y.; Hu, Z.; Zheng, Z.; Song, S.; Xu, Q.; Shen, Y.*; Deng, X.* Aspertetranones A-D, Meroterpenoids from the Marine Algal-associated Fungus Aspergillus sp. J. Nat. Prod. 2015, 78, 2405-10.
13. Deng, X.^#; Dzamko, N.^#; Prescott, A.; Davies, P.; Liu, Q.; Yang, Q.; Lee, J. D.; Patricelli, M. P.; Nomanbhoy, T. K.; Alessi, D. R.; Gray, N. S. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.Nat. Chem. Biol. 2011, 7, 203-5.
14. Yang, Q. ^#; Deng, X.^#; Lu, B. ^#; Cameron, M.; Fearns, C.; Patricelli, M. P.; Yates, J. R., 3rd; Gray, N. S.; Lee, J. D. Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell 2010, 18, 258-67.
15. Deng, X.^#; Okram, B. ^#; Ding, Q.^#; Zhang, J. ^#; Choi, Y.; Adrian, F. J.; Wojciechowski, A.; Zhang, G.; Che, J.; Bursulaya, B.; Cowan-Jacob, S. W.; Rummel, G.; Sim, T.; Gray, N. S. Expanding the diversity of allosteric bcr-abl inhibitors. J. Med. Chem. 2010, 53, 6934-46.






已授权的专利
[1] 邓贤明,周大旺, 陈兰芬, 何志祥, 樊福钦. 嘧啶类七元环化合物、其制备方法、药用组合物及其应用: 2020-3-27, 中国, ZL4.3.
[2]邓贤明,庄仲极, 邓舟, 黄晓星, 刘琰, 张婷, 黄伟, 徐庆妍, 胡志钰. PYRIMIDOPYRROLE COMPOUNDS, METHOD FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF: 2019-12-17,美国, 10,508,118 B2.
[3]邓贤明, 庄仲极, 邓舟, 黄晓星, 刘琰, 张婷, 黄伟, 徐庆妍, 胡志钰.PYRIMIDOPYRROLE COMPOUNDS, METHOD FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF: 2019-10-25, 日本, **.
[4]邓贤明, 庄仲极, 邓舟, 黄晓星, 刘琰, 张婷, 黄伟, 徐庆妍, 胡志钰. 嘧啶并吡咯类化合物、其制备方法、药用组合物及其应用: 2019-6-7, 中国, ZL5.4.
[5]邓贤明,徐庆妍,金铃,李小阳,王跃宙,胡志钰,郑忠辉,宋思扬.革耳氯烯酮类化合物及其制备方法和应用:2017-4-12, 中国, ZL3.5.